Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Functional disorder

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    718 result(s) found for: Functional disorder. Displaying page 1 of 36.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-000210-19 Sponsor Protocol Number: CRIT124D2302E1 Start Date*: 2011-06-10
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 6-month, open-label extension to a 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-on...
    Medical condition: Adult patients with childhood-onset Attention Deficit Hyperactivity Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10003735 Attention deficit-hyperactivity disorder LLT
    14.0 10037175 - Psychiatric disorders 10003737 Attention deficit/hyperactivity disorder NOS LLT
    14.0 10037175 - Psychiatric disorders 10003736 Attention deficit/hyperactivity disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) BE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-021533-31 Sponsor Protocol Number: CRIT124D2302 Start Date*: 2011-02-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD
    Medical condition: Adult patients with childhood-onset Attention Deficit Hyperactivity Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10003735 Attention deficit-hyperactivity disorder LLT
    14.1 10037175 - Psychiatric disorders 10003737 Attention deficit/hyperactivity disorder NOS LLT
    14.1 10037175 - Psychiatric disorders 10003736 Attention deficit/hyperactivity disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) BE (Completed) DK (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2010-023654-37 Sponsor Protocol Number: 34509 Start Date*: 2011-03-24
    Sponsor Name:Academic Medical Center
    Full Title: Effects of methylphenidate on the development of the dopaminergic system in the brain
    Medical condition: This project investigates whether the effects of methylfenidate on the outgrowth of the dopaminergic system are dependent on age. In a 16 week multicenter, dounle-blind, placebo controlled trial wi...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10037175 - Psychiatric disorders 10064104 ADHD LLT
    15.0 10022891 - Investigations 10056941 MRI brain LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-004180-13 Sponsor Protocol Number: OCARINA Start Date*: 2021-10-18
    Sponsor Name:KU Leuven
    Full Title: The effect of obeticholic acid on gut microbiota, gastric motility, accommodation, gastrointestinal peptide in healthy volunteers
    Medical condition: The study will focus on the underlying mechanisms of gastrointestinal motility and gut microbiota in healthy subjects.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10022891 - Investigations 10017782 Gastric emptying study PT
    20.1 100000004856 10061247 Intestinal functional disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-018161-12 Sponsor Protocol Number: SPD503-315 Start Date*: 2010-12-23
    Sponsor Name:Shire Development Inc
    Full Title: A Phase 3, Double-blind, Placebo-controlled, Multicentre, Randomised withdrawal, Long-term Maintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adol...
    Medical condition: Attention-Deficit/Hyperactive Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10068451 ADHD, combined type LLT
    14.1 100000004873 10068453 ADHD, predominantly inattentive type LLT
    14.1 100000004873 10068452 ADHD, predominantly hyperactive-impulsive type LLT
    14.1 100000004873 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed) ES (Completed) SE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002221-21 Sponsor Protocol Number: SPD503-312 Start Date*: 2011-08-30
    Sponsor Name:Shire Development Inc
    Full Title: A Phase 3, Double-blind, Randomized, Multi-center, Placebo controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once daily Dosing with Extended-release Guanfacin...
    Medical condition: Attention-Deficit/Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10068451 ADHD, combined type LLT
    14.0 10037175 - Psychiatric disorders 10068453 ADHD, predominantly inattentive type LLT
    14.0 10037175 - Psychiatric disorders 10068452 ADHD, predominantly hyperactive-impulsive type LLT
    14.0 10037175 - Psychiatric disorders 10064104 ADHD LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-006242-26 Sponsor Protocol Number: W004PS0108_1 Start Date*: 2009-10-27
    Sponsor Name:Universitätsklinikum Würzburg
    Full Title: Genetic modulation of functional brain activity of attention-deficit/hyperactivity disorder-related working memory processes
    Medical condition: Attention-deficit hyperactivity disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064104 ADHD LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001217-27 Sponsor Protocol Number: CONCERTAATT4092 Start Date*: 2015-04-24
    Sponsor Name:Janssen Korea Ltd
    Full Title: An Open-label Prospective Trial to Evaluate Functional Outcomes of OROS Methylphenidate in Children with ADHD (FOSCO)
    Medical condition: Attention Deficit Hyperactivity Disorder
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004873 10003735 Attention deficit-hyperactivity disorder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-004271-78 Sponsor Protocol Number: CIAOII Start Date*: 2016-05-31
    Sponsor Name:King's College London
    Full Title: Randomised controlled trial of the short term effects of OROS-methylphenidate on ADHD symptoms and behavioural outcomes in young male prisoners with attention deficit hyperactivity disorder
    Medical condition: Attention Deficit Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10064104 ADHD LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000215-32 Sponsor Protocol Number: Pycno2015-14 Start Date*: 2016-10-04
    Sponsor Name:University of Antwerp
    Full Title: Effect of Pycnogenol® on Attention-Deficit Hyperactivity Disorder (ADHD): A randomized, double blind, placebo and active product controlled multicenter trial.
    Medical condition: Attention-deficit hyperactivity disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10003737 Attention deficit/hyperactivity disorder NOS LLT
    19.0 10037175 - Psychiatric disorders 10003736 Attention deficit/hyperactivity disorder PT
    19.0 10037175 - Psychiatric disorders 10003735 Attention deficit-hyperactivity disorder LLT
    19.0 10037175 - Psychiatric disorders 10003734 Attention deficit disorder of childhood without mention of hyperactivity LLT
    19.0 10037175 - Psychiatric disorders 10003733 Attention deficit disorder of childhood with hyperactivity LLT
    19.0 10037175 - Psychiatric disorders 10003732 Attention deficit disorder of childhood LLT
    19.0 10037175 - Psychiatric disorders 10003731 Attention deficit disorder LLT
    19.0 100000004852 10003729 Attention concentration difficulty LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000679-90 Sponsor Protocol Number: SPD489-325 Start Date*: 2009-04-08
    Sponsor Name:Shire Pharmaceutical Development Limited
    Full Title: A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and ...
    Medical condition: Attention Deficit / Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FR (Completed) ES (Completed) NL (Completed) SE (Completed) BE (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2008-000720-10 Sponsor Protocol Number: SPD489-326 Start Date*: 2008-11-20
    Sponsor Name:Shire Pharmaceutical Development Limited
    Full Title: A Phase III, Double- Blind, Placebo- Controlled, Randomised Withdrawal, Multicentre, Extension, Safety and Efficacy of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 with A...
    Medical condition: Attention Deficit / Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) NL (Completed) SE (Completed) BE (Completed) GB (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-011745-94 Sponsor Protocol Number: SPD489-317 Start Date*: 2009-10-19
    Sponsor Name:Shire Pharmaceutical Development Limited
    Full Title: A Phase 3b, Double-blind, Randomised, Active-controlled, Parallel-group Study to Compare the Time to Response of Lisdexamfetamine Dimesylate to Atomoxetine Hydrochloride in Children and Adolescents...
    Medical condition: Attention Deficit/Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10003736 Attention deficit/hyperactivity disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) FR (Completed) ES (Completed) BE (Completed) PL (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-014444-11 Sponsor Protocol Number: RET04.09 Start Date*: 2009-08-10
    Sponsor Name:IRCCS- FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA-ONLUS
    Full Title: Functional and morphological retinal changes in diabetic macular edema treated with pegaptanib
    Medical condition: Diabetic Macular Edema
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038901 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000419-98 Sponsor Protocol Number: B4Z-US-LYEI Start Date*: 2021-12-13
    Sponsor Name:Eli Lilly and Company
    Full Title: Neurophysiology of Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Dyslexia: Functional Magnetic Resonance Imaging (fMRI) Measures of Brain Activation During Attention and Reading Tas...
    Medical condition: Attention Deficit Hyperactivity Disorder, Dyslexia.
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004873 10003735 Attention deficit-hyperactivity disorder LLT
    20.0 10029205 - Nervous system disorders 10013932 Dyslexia PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-022991-29 Sponsor Protocol Number: SMR/0211OBD-1033 Start Date*: 2011-02-01
    Sponsor Name:Sucampo Pharma Americas, Inc.
    Full Title: A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Patients with Opioid-induced Bowel Dysfunction
    Medical condition: Opioid-induced Bowel Dysfunction
    Disease: Version SOC Term Classification Code Term Level
    14.0 10017947 - Gastrointestinal disorders 10061247 Intestinal functional disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) SE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2016-004023-24 Sponsor Protocol Number: PRETEC-EPO Start Date*: 2016-12-15
    Sponsor Name:Copenhagen Affective Disorder research Center (CADIC), Psychiatric Centre Copenhagen, Rigshospitalet
    Full Title: Effect of erythropoietin (EPO) on cognitive function and frontal lobe activity in patients with bipolar disorder and unipolar depression in remission (PRETEC-EPO)
    Medical condition: Bipolar disorder and unipolar depression
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057667 Bipolar disorder PT
    21.1 10037175 - Psychiatric disorders 10045543 Unipolar depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-022706-41 Sponsor Protocol Number: NIC - 05 (NOCRY-a) Start Date*: 2010-11-08
    Sponsor Name:MENARINI RICERCHE S.P.A.
    Full Title: Double-blind, randomised, placebo-controlled, parallel group pilot study to evaluate the efficacy and safety of oral administration of Nepadutant in infant colic babies not responder to conventiona...
    Medical condition: Infant colic
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061247 LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004294-87 Sponsor Protocol Number: 1,2 Start Date*: 2011-11-15
    Sponsor Name:Per Klausen Fink
    Full Title: Treatment of multi-organ bodily distress syndrome. A double-blinded placebo controlled trial of the effect of Imipramine (STreSS-3)
    Medical condition: F 45 Somatisation disorder and related disorders. Bodily distress syndrome is a new diagnosis that resembles F 45 Somatisation disorder, but with a more specific set of diagnostic criteria.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10041326 Somatoform disorders HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-001556-11 Sponsor Protocol Number: 1058 Start Date*: 2011-05-23
    Sponsor Name:IRCCS FONDAZIONE STELLA MARIS
    Full Title: Decline of mentale functions in adults with Down Syndrome: clinical and experimental study on the effects of treatment with fluoxetine and of cognitive and physical training.
    Medical condition: Adults (over 30 years) with Down Syndrome.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10040442 Severe imbecility LLT
    14.1 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 07:58:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA